Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST trial of niraparib versus placebo in ctDNA-positive high-risk early HER2-negative breast cancer
NL-OMON52131Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and triple-negative breast cancer (TNBC) comparing Niraparib with Placebo (2 arms). Primary endpoints: Disease-free survival and Safety and tolerability. Started Aug 2021; status: recruiting.
02
Drugs
niraparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON52131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52131.